Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBPP) Net Margin (2016 - 2025)

Historic Net Margin for Regen BioPharma (RGBPP) over the last 11 years, with Q3 2025 value amounting to 964.3%.

  • Regen BioPharma's Net Margin fell 8532900.0% to 964.3% in Q3 2025 from the same period last year, while for Dec 2025 it was 427.68%, marking a year-over-year decrease of 806900.0%. This contributed to the annual value of 538.76% for FY2025, which is 2562700.0% down from last year.
  • According to the latest figures from Q3 2025, Regen BioPharma's Net Margin is 964.3%, which was down 8532900.0% from 283.23% recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's Net Margin registered a high of 103772.21% during Q2 2022, and its lowest value of 114926.74% during Q1 2022.
  • For the 5-year period, Regen BioPharma's Net Margin averaged around 1187.69%, with its median value being 198.27% (2024).
  • Data for Regen BioPharma's Net Margin shows a peak YoY increase of 1169966200bps (in 2022) and a maximum YoY decrease of -1163198000bps (in 2022) over the last 5 years.
  • Over the past 5 years, Regen BioPharma's Net Margin (Quarter) stood at 4048.19% in 2021, then crashed by -39bps to 2452.28% in 2022, then plummeted by -110bps to 245.34% in 2023, then crashed by -256bps to 872.57% in 2024, then decreased by -11bps to 964.3% in 2025.
  • Its last three reported values are 964.3% in Q3 2025, 283.23% for Q2 2025, and 32.77% during Q1 2025.